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SECOND TRANSPLANT FOR ACUTE MYELOGENOUS LEUKEMIA RELAPS-
ING AFTER FIRST TRANSPLANT
Kim, H.-J., Min, W.-S., Eom, K.-S., Cho, B.-S., Lee, S., Min, C.-K.,
Cho, S.-G., Kim, D.-W., Lee, J.-W., Kim, C.-C. Catholic HSCT Cen-
ter, St. Mary’s Hospital, Seoul, Republic of Korea.
Second hematopoietic stem cell transplantation (HSCT) may be
an effective salvage therapy in some patients with acute myeloge-
nous leukemia (AML) who relapse after an initial transplant. To in-
vestigate the availability of second HSCT, we reviewed our medical
records of 10 recipients of second allogeneic transplants for leuke-
mia recurring after initial autologous or allogeneic transplantation.
Since year 2002, ten relapsed patients after first HSCT who re-
ceived second HSCT from the available HLA-matched (N 5 7)
or –mismatched (N 5 3) sibling or unrelated donors were retro-
spectively reviewed. The median patient age was 35 (range,
1851) and there were 6 males and 4 females. The median fol-
low-up duration after second transplant was 14 months (range, 4–
59). The majority of patients had intermediate or unfavourable
cytogenetic features. Seven patients were relapsed after autologous
HSCT, as a first transplant. Others received from HLA-matched
sibling donors. The main conditioning regimen for second trans-
plant consisted in cyclophosphamide plus busulfan. For graft-ver-
sus-host-disease (GVHD) prophylaxis, we used combinations of
cyclosporine A or tacrolimus in addition to short-term methotrex-
ate. In all, 6 patients received peripheral blood stem cells. All trans-
planted patients were successfully engrafted. The overall incidence
of acute and chronic GvHD was 60% and 43%, respectively. Two
(20%) patients were relapsed so far. The estimated probability of
disease-free survival rate at 4-year was 50%. The overall 5-year sur-
vival rate was 55%. When we considered the incidence of non-re-
lapse transplant-related mortality (TRM), two recipients (20%)
died due to one from severe acute GvHD and the other from fatal
infectious cause. These results demonstrate that second HSCT
for relapsed AML patients performed with appropriate clinical
schedule is feasible, and is associated with a favourable outcome.Characteristics of patients
StemDiagnosis Age/Sex Cytogenetics1st
transplant2nd
transplantcell
source Conditioning StatusAML, M1 33/F 46 XX Sib allo Sib allo PBSC Busulfex/
CyAlive,
50 mAML, M1 36/M t(8;21),21q,14 Auto Unrelated PBSC Busulfex/Cy/
ATGDied,
4 mAML, M2 35/M inv(16) Auto Sib allo PBSC Busulfex/
CyAlive,
11 mAML, M4 46/M 46 XY Sib allo Sib allo PBSC Busulfex/
CyAlive,
53 mAML, M2 49/F 45 X,-9 Auto Unrelated BM Busulfex/Cy/
ATGAlive,
19 mAML, M2 44/F t(1;1) Auto Unrelated BM Busulfex/Cy Alive,
59 mAML, M2 35/M del(16) Auto Unrelated BM Busulfex/Cy/
ATGDied,
12 mAML, M1 21/F inv(16) Auto Sib allo BM Busulfex/Cy Died,
6 mAML, M5 34/M 47 XX,121,
add(3),
add(15),
t(4;18)Sib allo Sib allo PBSC Busulfex/
Fludarabine/
Ara-CAlive,
6 mAML, M1 18/F 47 XX,121 Auto Sib allo PBSC Busulfex/Cy Died,
24 mIDA/BHAC, idarubicin/N4-behenoyl-1-b-Darabinofuranosylcy-
tosine; FLANG, fludarabine, Ara-C, mitoxantrone, and G-
CSF combination chemotherapy in a sequence manner; Topo,
topotecan; M, mitoxantrone; Vp, etoposide; Cy, cyclophospha-
mide; ATG, anti-thymocyte globulin; TRM, transplant-related
mortality; CR2, second complete remission; CTx, chemother-
apy; F/U, follow-up.326
ONCE DAILY BUSULFAN AND FLUDARABINE IS WELL TOLERATED AND
EFFECTIVE IN OLDER HEAVILY TREATED PATIENTS PRIOR TO UNRE-
LATED DONOR ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANS-
PLANT
Potter, G.W., Bachier, C., Smith, B., Houghman, M., LeMaistre, C.F.,
Shaughnessy, P.J. Texas Transplant Institute, San Antonio, TX.
We report the results of a prospective phase II study using a re-
duced intensity (RI) regimen and unrelated donor hematopoietic
stem cell transplant (HCT) consisting of intravenous busulfan
(Bu) 3.2 mg/kg daily for 2 doses, fludarabine 30 mg/m2 daily
for 5 doses, and ATG 15 mg/kg daily for 4 doses. GVHD pro-
phylaxis was tacrolimus and methotrexate 15 mg/m2 on day 1,
and 10 mg/m2 on days 3 and 6. Twenty-one patients (median
age 60, range 39–67) were treated; 19 were HLA matched with
unrelated donors at A, B, C, DR, and DQ, and 2 pts had unre-
lated donors mismatched at one HLA class I allele, and 9 pts had
one or more autologous HCTs prior to beginning the study. Fol-
low up data is available on 20 pts. Grade II or higher regimen
related toxicity (RRT) was reported in seventeen (85%) pts; gas-
trointestinal (n 5 14), mucositis (n 5 7), hepatic function (n 5
4), fever and infection (n 5 3), pulmonary function (n 5 2),
and renal function (n 5 1). Veno-occlusive disease did not man-
ifest in any pts. Six pts did not receive the full dosage of ATG
because of ATG toxicities, including fever and chills, hypoten-
sion, capillary leak syndrome, and elevated bilirubin levels. The
median day of engraftment was 15 days and 19 (95%) of twenty
pts achieved 100% donor chimerism by day 80. Three pts subse-
quently lost donor chimerism and one never achieved higher than
90% donor chimerism; all 4 pts relapsed. Thirteen pts (65%) de-
veloped grade II or higher overall acute GHVD and chronic
GVHD developed in five pts. Treatment related mortality
(TRM) was 15% (95% confidence interval [CI], 5%-40%) at 3
months, and 35% (95% CI, 17%-63%) at 12 months. The
most common cause of TRM was GVHD and infection. Actuar-
ial overall survival at 3 years was 52% (95% CI, 27%-71%). All
six pts who received reduced ATG dosages developed acute
GVHD and one had relapse of disease, while of the remaining
fourteen pts who received full ATG dosages 7 developed acute
GVHD and 5 had relapse of disease. In conclusion, once daily
Bu and fludarabine and unrelated donor HCT demonstrated
good long term survival and disease control, however, TRM still
exists with this regimen in this heavily treated, older pt popula-
tion. Future use of a co-morbidity scoring tool may help select
pts more suitable for this regimen. ATG significantly contributed
to RRT, while GVHD and its treatment and complications pri-
marily resulted in the TRM. Removing ATG and using other
measures for GVHD prophylaxis and treatment may improve
this RI regimen.327
SAFETY AND TOXICITY OF REDUCED INTENSITY ALLOGENEIC TRANS-
PLANTATIONWITH FLUDARABINE/MELPHALAN IN PATIENTSWITH AD-
VANCED HAEMATOLOGICAL DISEASES. A SINGLE CENTRE EXPERIENCE
Khoo, L., Johnston, A.-M., Larsen, S., Joshua, D., Gibson, J. Royal
Prince Alfred Hospital, Sydney, New South Wales, Australia.
Aim: The safety and toxicity outcomes in a group of patients
with advanced haematological diseases undergoing reduced inten-
sity allogeneic stem cell transplantation using Fludarabine (30
mg/m2) and Melphalan (140 mg/m2) conditioning was examined.
The majority (62%) of these heavily pre-treated patients had
failed previous transplantation (22 autologous, and 1 allogeneic).
Method: Thirty-seven patients underwent Sibling (Full Match) -
19; Mismatch Sibling/Other Family – 4, MatchedUnrelated Donor
– 13 or Umbilical Cord Blood – 1 transplantation. The median pa-
tient age was 50 years (range, 29 – 64 years). Disease at time of trans-
plant was: 6 primary acute leukaemia, 3 secondary acute leukaemia,
3 secondaryMDS, 1 primaryMDS, 11 multiple myeloma, 12 NHL
and 1 myelofibrosis. Results: The median follow-up period was 21
months (range, 0.2 – 84 months. Median survival was 9 months
